^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET inhibitor

    Related drugs:
    21h
    OrigAMI-5: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • Rybrevant (amivantamab-vmjw)
    1d
    Clinical case report on the efficacy and safety of savolitinib in elderly patients with non-small cell lung cancer harboring METex14 skipping mutations. (PubMed, Transl Cancer Res)
    They were treated with savolitinib as the second-line treatment after previously receiving AP regimens (pemetrexed + cisplatin). The case series demonstrated that savolitinib has a favorable clinical efficacy and safety profile, suggesting its potential as a key therapeutic option for elderly patients with NSCLC harboring METex14 skipping mutations. The treatment offers sustained survival benefits and is well-tolerated.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    cisplatin • pemetrexed • Orpathys (savolitinib)
    3d
    Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study. (PubMed, Lancet Oncol)
    Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.
    P2 data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    bozitinib (APL-101)
    7d
    Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar (clinicaltrials.gov)
    P3, N=62, Recruiting, Kringle Pharma, Inc. | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    7d
    METalmark: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: May 2028 --> Mar 2027
    Trial completion date
    |
    Rybrevant (amivantamab-vmjw) • Tabrecta (capmatinib)
    9d
    Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P1 trial
    9d
    Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer. (PubMed, Ecancermedicalscience)
    Utilising a robust next-generation sequencing platform, we have identified this mutation in 5.3% of cases in our cohort. In the absence of information on MET exon 14 skipping from India, this case series will throw some light on this variation in our subcontinent and highlights the fact that the real-world effectiveness of MET inhibitors like Tepotinib and Capmantinib might be lower than expected.
    Journal • Real-world evidence
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    Tepmetko (tepotinib)
    10d
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    11d
    Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. (PubMed, J Clin Oncol)
    In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    15d
    Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. (PubMed, Clin Lung Cancer)
    Savolitinib plus osimertinib demonstrated numerically higher clinical activity versus savolitinib plus placebo in all patients and patients with higher MET biomarker cutoffs.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    16d
    Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report. (PubMed, Oncol Lett)
    The present study marks the initial discovery of MET exon 14 skipping and EGFR Del19 in a single patient, who achieved partial response through a treatment plan involving Osimertinib and Gumarontinib. These findings provide valuable perspectives on treatment approaches for individuals sharing similar genetic profiles.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET exon 14 mutation • MET mutation
    |
    Tagrisso (osimertinib) • Haiyitan (gumarontinib)
    17d
    swalloWTail: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial primary completion date
    |
    docetaxel • Rybrevant (amivantamab-vmjw)